Topic: Health
A large study found that new blood thinners reduced stroke risk by 69% in people with a heart condition called atrial fibrillation. The study, led by Professor Boyoung Joung from Yonsei University in South Korea, involved 1,803 patients and was published in the New England Journal of Medicine.
Atrial fibrillation (AF) is a common heart rhythm disorder that can increase the risk of blood clots and stroke. The European Society of Cardiology recommends oral anticoagulants for people with AF who are at high risk of stroke, but for those at intermediate risk, the recommendation is less clear.
The SINGLE-AF trial was conducted to provide evidence on whether newer direct oral anticoagulants (DOACs) are beneficial in patients with AF at intermediate risk of stroke. DOACs are a type of blood thinner that work by preventing blood clots from forming.
In the study, 1,803 people with AF were enrolled and randomly assigned to receive either apixaban or rivaroxaban (two types of DOACs) or no anticoagulation at all. After 24 months, researchers found a 69% reduction in serious cardiovascular events among patients taking DOACs compared to those receiving no anticoagulation.
The primary endpoint was the combination of stroke, systemic embolism, major bleeding, and cardiovascular death. The study found that ischemic strokes (strokes caused by blood clots) occurred in 0.1% of patients taking DOACs compared to 1.1% of those receiving no anticoagulation.
The trial did not find an increase in major bleeding among patients taking DOACs, which is a common concern with blood thinners.
Why It Matters
This study's findings could lead to changes in treatment guidelines for people with atrial fibrillation and may help reduce the risk of stroke in India, where AF is a growing health concern. With over 20 million Indians living with AF, this research has significant implications for public health policy.
Key Facts
- 1,803 patients were enrolled in the SINGLE-AF trial to study the effectiveness of newer blood thinners in reducing stroke risk.
- The study found a 69% reduction in serious cardiovascular events among patients taking DOACs compared to those receiving no anticoagulation.
- Ischemic strokes occurred in 0.1% of patients taking DOACs, compared to 1.1% of those receiving no anticoagulation.
- The trial did not find an increase in major bleeding among patients taking DOACs.
- The study was published in the New England Journal of Medicine on September 24, 2026.
Key Terms
- Atrial fibrillation
- A common heart rhythm disorder that can increase the risk of blood clots and stroke.
- Direct oral anticoagulants (DOACs)
- Newer types of blood thinners that work by preventing blood clots from forming.
Implications
This study's findings could lead to changes in treatment guidelines for people with atrial fibrillation and may help reduce the risk of stroke in India, where AF is a growing health concern. With over 20 million Indians living with AF, this research has significant implications for public health policy.
Leave a comment